Juxiechang

Beijing Juxiechang Pharmaceutical is a prominent Chinese pharmaceutical firm dedicated to the modernization and production of Traditional Chinese Medicine (TCM). The company's core business revolves around respiratory health, with its flagship product, Shufeng Jiedu Capsules, serving as a leading treatment for influenza and viral pneumonia in China. Juxiechang has gained international recognition through clinical collaborations, including research with the University of Oxford to evaluate the efficacy of its herbal formulations. The company maintains integrated operations from R&D to large-scale GMP manufacturing, primarily serving the domestic Chinese market. During the COVID-19 pandemic, its products were extensively utilized and included in national clinical guidelines.